Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe the issue is with Yahoo not ADXS
I am able to get on the message board with one of my home computers but not with any others
456,000 shares available @ .075
anyone interested?
Advaxis Appoints Daniel J. O’Connor President and CEO and Elects Dr. James Patton Non-Executive Chairman of the Board
Advaxis, Inc. (ADXS) (“Advaxis” or the “Company”), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the appointment of Daniel J. O’Connor, formerly Executive Vice President, to the position of President and Chief Executive Officer. Mr. O’Connor has also joined the Board of Directors. Dr. James Patton, currently the Chairman of the Audit Committee, has been elected Non-Executive Chairman of the Board. Thomas A. Moore, formerly Chairman and Chief Executive Officer of Advaxis, will continue to serve on the Board of Directors and as a consultant to the Company.
Mr. O’Connor has fifteen years of executive experience in the biopharmaceutical industry with ImClone Systems, formerly (NASDAQ:IMCL), PharmaNet (now inVentiv Health Clinical), and Bracco Diagnostics. As ImClone’s Senior Vice President, he played a key role in resolving numerous issues facing ImClone and closed several important deals leading to its sale to Eli Lilly (LLY) in 2008.
Dr. Patton is a founding member of the Advaxis Board of Directors, an internist, and the Vice President of Millennium Oncology Management, Inc., which provides management services in oncology. Dr. Patton is also an Independent Trustee for the DundeeWealth U.S. mutual fund family and a founder and chairman of VAL Health, LLC, a healthcare consulting company.
Dr. Patton stated, “We sincerely thank Tom Moore for his tireless efforts leading Advaxis for the last 6+ years. Importantly, the ADXS-HPV proprietary technology platform has achieved proof of concept and Tom has assembled an experienced management team to continue to advance the clinical pipeline. Over the past six months, the Advaxis team has accelerated its licensing negotiations, achieved several clinical milestones including the recent designation of orphan drug status for ADXS-HPV in anal cancer, and has worked to improve its balance sheet; all of which have been fundamental advancements of the Company’s business. However, we know there still is a lot to accomplish to take Advaxis to the next platform and we remain focused on the goal of unlocking significant stockholder value.”
“The Company is now entering a transformational phase, and Dan’s appointment as CEO is the outcome of Tom and the Board’s succession planning initiatives over the past year in preparation for this important time. Dan has brought tremendous energy to Advaxis since joining in January, and we believe his industry experience and professional track record are perfectly aligned with the Company’s strategic priorities,” concluded Dr. Patton.
Mr. O’Connor stated, “I am very pleased to be appointed to lead Advaxis at this pivotal point in its drug development and commercialization efforts, and I am prepared for this challenge. The Company’s innovative science and IP hold great promise for addressing many important areas of unmet medical needs. We have an excellent team in place, and together we will be focused on continuing to fundamentally transform the Company on multiple fronts, including the preparation for our registration studies with ADXS-HPV and continuing to strengthen our balance sheet. I would like to thank the Board of Directors and Tom for their vote of confidence in me, the Advaxis team for their commitment to the success of the Company, and our stockholders for their continued support over the past several months and in the years ahead.”
Thomas A. Moore added, “I am grateful for having had the opportunity to lead Advaxis and wholeheartedly believe this is the right time for Dan to transition to CEO of the Company. I will work in every way to support Dan, the Board, and the team in their expected coming accomplishments and am pleased to work with the Company as a consultant during this time. I will continue to be a significant stockholder and Director of Advaxis, and will support the Company as needed in the future.”
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
For more information please visit: www.advaxis.com
Contact:
Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
dmoore@advaxis.com
or
Jenene Thomas Communications, LLC
Jenene Thomas, 908-938-1475 Investor Relations and Corporate Communications Advisor
thomasjenene@gmail.com
it was a sell because the seller hit the bid
it doesn't make a difference what the last price was
I believe that they are mandated to release that information on a timely basis
Either way, I think this gives us the credibility that we needed
for our lead drug candidate, ADXS-HPV.
Advaxis’ ADXS-HPV Granted Orphan Drug Designation for Treatment of HPV-Associated Anal Cancer
PRINCETON, N.J.--(BUSINESS WIRE)--
Advaxis, Inc., (ADXS), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for ADXS-HPV, its lead drug candidate, for the treatment of human papillomavirus (HPV)-associated anal cancer.
Orphan Drug Designation is granted to drug therapies intended to treat diseases or conditions that affect fewer than 200,000 people in the United States. Orphan Drug Designation entitles the sponsor to clinical protocol assistance with the FDA, as well as federal grants, tax credits, and potentially a seven year market exclusivity period.
“We are very pleased to have been granted an orphan drug designation for ADXS-HPV in this unmet medical need,” commented Dr. Robert Petit, Chief Scientific Officer of Advaxis. “Patients with anal cancer have limited treatment options and we hope to improve their survival by developing ADXS-HPV for this indication. We will continue the ongoing Phase 1/2 study being coordinated by Brown University Oncology Group that is evaluating the safety and efficacy of ADXS-HPV when combined with standard chemotherapy and radiation treatment in patients with anal cancer.”
About Orphan Drug Designation
Under the Orphan Drug Act (ODA), the FDA may grant orphan designation to a drug or biological product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making a drug or biological product available in the United States for this type of disease or condition will be recovered from sales of the product. The benefits of orphan drug designation can be substantial and include federal grants, tax credits, and potentially a seven year market exclusivity period once the product is approved, provided that the product is first to market.
In order for a sponsor to obtain orphan designation for a drug or biological product, an application must be submitted to OOPD, and the designation approved. The approval of an application for orphan designation is based upon the information submitted by the sponsor. A drug that has obtained orphan designation is said to have “orphan status.” Each designation request must stand on its own merit. Sponsors requesting designation of the same drug for the same indication as a previously designated product must submit their own data in support of their designation request. The approval of an orphan designation request does not alter the standard regulatory requirements and process for obtaining marketing approval. Safety and efficacy of a compound must be established through adequate and well-controlled studies.
About ADXS-HPV
ADXS-HPV is an immunotherapy that is designed to target cells expressing the HPV gene E7. Expression of the E7 gene from high-risk HPV variants is responsible for the transformation of infected cells into dysplastic and malignant tissues. Eliminating these cells can eliminate the dysplasia or malignancy. ADXS-HPV is designed to infect antigen-presenting cells and direct them to generate a powerful, cellular immune response to HPV E7. The resulting cytotoxic Tcells infiltrate and attack the tumors while specifically inhibiting tumor Tregs and MDSCs in the tumors that are protecting it.
About Anal Cancer
Anal cancer is a malignancy of the lower gastrointestinal tract, with an estimated 7,060 new cases in the United States in 2013. The most common pathologic type of anal cancer is squamous cell carcinoma (SCCA), which accounts for approximately 85% of all cases. The remaining cases comprise anal adenocarcinoma (10%) and other types (5%). Approximately 20%-40% of patients present with lymph node involvement and approximately 10% present with metastatic disease.
The incidence of anal cancer is increasing. From 1973-2000, the incidence of anal cancer in the United States increased by 160% among men and by 78% among women. An estimated 84% of anal carcinomas are caused by HPV. The risk of anal cancer is substantially increased in HIV-infected individuals, and an estimated 28% of males with anal cancer during 2001-2005 were HIV-infected.
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others.
For more information please visit: www.advaxis.com
Forward-Looking Statements
This news release contains forward-looking statements, including, but not limited to: statements regarding ADXS-HPV improving survival rates for patients with HPV-associated anal cancer. These forward-looking statements are subject to a number of risks, including the risk factors set forth from time to time in Advaxis' SEC filings, including but not limited to its report on Form 10-K for the fiscal year ended October 31, 2012, which is available at http://www.sec.gov. Advaxis undertakes no obligation to publicly release the result of any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events, except as required by law. You are cautioned not to place undue reliance on any forward-looking statements.
Contact:
Advaxis, Inc.
Diana Moore, 609-452-9814
Director, Investor Relations & Business Development
dmoore@advaxis.com
legally, they are limited to the amount of shares they can own
re: DNDN
the stock was down 26% on lower sales. mgmt said that investors do not understand immunotherapy - I believe that the $70K cost is what is causing the problem. Who knows how much longer SS willpay claims if they do now?
ADXS will begin prostate trials in early 2014. Those who look
longer term will prosper while others will continue to complain
IMHO
I have noticed this as well. There is a buyer at the $3.20 level
The "D" should be off by Monday and maybe they have been holding back news
AMEN
Glad you said it - I have been thinking that way for a long time
They must have another agenda wouldn't you say?
I use Scottrade and can trade the stock with the D
The company issued a press release on 7/25 so I don't think that the issue
James:
I have called and emailed TM but have not got a response to anything about orphan status
Let's hope for the best
James:
Today is 08/01
I would think we should hear something by next week in reference to orphan status.
Let's hope for the best
I agree Bruce
The conv debt is nothing - it's part of staying in business
How else can they fund company until we get production?
I guess you were right!!!
I am looking long term
I think we can have a 100M+ mkt cap within 12-18 months if the
projections are correct or we exceed them
your thoughts?
Do you think we will see production from Ruby in 2013?
I have done a lot of DD and truly love NBRI
Once we see production, the price will start to move up and you will be right about $1+ next year
Is there any way to put people like you on "ignore"
Honestly, nobody really cares how much you have lost or what you think. People like you should really be buying CD's
When I take a loss on a stock I never watch it or post a message
Act like a pro and go away
I am still hopeful that ADXS will work out in the future. However,
if my opinion changes, I will never post again and will never whine
What we need is ......
Production, Production, Production
I have a call out to TM - we will see if he responds
He told me before the r/s that they would only do it if the stock was north of .10 or if there was a compelling reason
What is the compelling reason?
Is something positive going to happen soon?
Let's hope so
James:
Have you spoken to Dan since the r/s?
I have reached out to the CFO but have not heard anything back
yet
We should hear something about orphan status the first week of August
Let's hope for the best
James:
I have seen you on the Yahoo message board. Will that board be back before the D is removed or do we have to wait 20 trading days?
I thought the r/s wouldn't happen till the stock was higher or they had significant news. Orphan status is due in a couple of weeks. Any thoughts?
Our mkt cap is about 18M - do you believe it?
Any other boards that we can communicate on?
I agree
I will adding as well
Detroit declare bankruptcy - who's next?
I think this board is being controlled by the PROGRESSIVES
You know there motto
DON'T DO WHAT I DO - DO WHAT I SAY
I AM OUT OF HERE
GOOD RIDDANCE
1:125 reverse split shares hit my Scottrade accounts and thus I am able to sell them
I think that is the weakness today as sellers are able to sell
despite positive PR the last few days
I still believe it is a buying opportunity
I don't believe that this selling is from individuals but from institutions liquidating their positions
PRINCETON, N.J.--(BUSINESS WIRE)-- 07-16-13
Advaxis, Inc., (OTCQB:ADXS and ADXSD), a leader in developing the next generation of immunotherapies for cancer and infectious diseases, announced the appointment of David Sidransky, MD to its Board of Directors.
Dr. Sidransky is a renowned oncologist and research scientist named and profiled by TIME magazine in 2001 as one of the top physicians and scientists in America, recognized for his work with early detection of cancer. Since 1994, Dr. Sidransky has been the Director of the Head and Neck Cancer Research Division and Professor of Oncology, Otolaryngology, Genetics, and Pathology at Johns Hopkins University School of Medicine.
He has served as Chairman of the Board of Directors of Champions Oncology since October 2007 and was, until the merger with Eli Lilly, a director and Vice-Chairman of ImClone Systems, Inc. He is the Chairman of Tamir Biotechnology and serves on the Board of Directors of Rosetta Genomics, Immune Pharmaceuticals, and Celsus. He is serving and has served on scientific advisory boards of MedImmune, Roche, Amgen, and Veridex, LLC (a Johnson & Johnson diagnostic company), among others. Dr. Sidransky served as Director (2005-2008) of the American Association for Cancer Research (AACR).
“David’s extensive experience with both the science and business of oncology makes him an ideal addition to the Board of Directors of Advaxis,” commented Thomas A. Moore, Chairman and Chief Executive Officer of Advaxis. “His guidance and high standards will be invaluable in the advancement of Advaxis’ novel technology to registrational trials and beyond.”
About Advaxis, Inc.
Advaxis is a clinical-stage biotechnology company developing the next generation of immunotherapies for cancer and infectious diseases. Advaxis immunotherapies are based on a novel platform technology using live, attenuated bacteria that are bio-engineered to secrete an antigen/adjuvant fusion protein(s) that is designed to redirect the powerful immune response all human beings have to the bacterium to the cancer itself.
ADXS-HPV is currently being evaluated in four clinical trials for human papillomavirus (HPV)-associated cancers: recurrent/refractory cervical cancer (India), locally advanced cervical cancer (GOG/NCI U.S. study, Clinical Trials.gov Identifier NCT01266460), head & neck cancer (CRUK study, Clinical Trials.gov Identifier NCT01598792), and anal cancer (BrUOG study, Clinical Trials.gov Identifier NCT01671488). Advaxis has over 15 distinct immunotherapies in various stages of development, developed directly by Advaxis and through strategic collaborations with recognized centers of excellence such as: the National Cancer Institute, Cancer Research – UK, the Wistar Institute, the University of Pennsylvania, the University of British Columbia, the Karolinska Institutet, and others. For more information please visit: advaxis.com | Facebook | twitter | LinkedIn
ATTENTION SHORTERS
YOU WILL LOSE A LOT OF MONEY
YOU HAVE BEEN WARNED!!!
I think you are right
Our mkt cap is less than 7M
Things can only get better IMHO
I have been reading your posts for the last year and appreciate your dedication and work
However, don't you think that until we get significant production our stock will languish?
long and strong